The combination therapy, which often includes drugs such as nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4), works by simultaneously ‘priming’ and ‘enhancing’ T-cell responses to release an antitumor potential against the tumor [33,180]. This evidence concerns the gene CTLA4 and neoplasm.